Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | Phase I study of B440, a WT1 cancer vaccine, in patients with metastatic urothelial cancer

Margaret Gatti-Mays • 1 Jun 2025
ASCO 2025
Genitourinary Cancer Urothelial Carcinoma B440

Margaret Gatti-Mays, MD MPH, The Ohio State University, Columbus, OH, discusses findings from a Phase I study of B440, an oral Bifidobacterium-engineered WT1 cancer vaccine, in patients with metastatic urothelial cancer. B440 exhibited a favourable safety profile, and improved progression-free survival, supporting further investigation in larger trials. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Margaret Gatti-Mays

Strategies to overcome barriers in cancer vaccine efficacy
1:32
Strategies to overcome barriers in cancer vaccine efficacy
Margaret Gatti-Mays • 1 Jun 2025
Phase I trial of a therapeutic vaccine with checkpoint inhibitors for FLC
1:28
Phase I trial of a therapeutic vaccine with checkpoint inhibitors for FLC
Margaret Gatti-Mays • 1 Jun 2025
SYNC-T therapy: in situ personalized cancer vaccination with intratumoral immunotherapy in mCRPC
2:04
SYNC-T therapy: in situ personalized cancer vaccination with intratumoral immunotherapy in mCRPC
Margaret Gatti-Mays • 1 Jun 2025
TGFβi NKs with naxitamab and gemcitabine for GD2+ breast cancer
2:45
TGFβi NKs with naxitamab and gemcitabine for GD2+ breast cancer
Margaret Gatti-Mays • 12 Dec 2024

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals